Speaker Profile

Ph.D., National Segment Director, Neurology, Specialty Medicine, Labcorp

Dr Volpe graduated from Duke University in 2008 with PhD in computational biology and bioinformatics, with a concentration in immunology. His research involved developing a software algorithm to decipher the germline origins of human immunoglobulin and T-cell receptors and then using that software to analyze large data sets of human antibodies to understand their diversity. He received the American Association of Immunologists-Huang Foundation Young Investigator Award in 2007 for his work in anti-HIV antibody composition. Upon graduating, Dr Volpe worked as a Medical Science Liaison at Monogram Biosciences where he covered the Southeast and Midwest territories. In early 2016 he became the Director of Scientific Outreach, helping to build the Medical Science Liaison team for Labcorp. In early 2018, Dr Volpe began putting together the pieces of what would become Labcorp’s Neurology initiative and he is now the National Segment Director for that program, which covers all of neurology with a focus on neurodegenerative diseases.

Clinical Dx Showcase:

We work day and night, around the world, to deliver answers for all your health questions—whether you’re a provider, drug developer, hospital, medical researcher or patient. That means everything from advancing diagnostic testing, to helping launch new drugs, to offering new perspectives through data, all drawing from a deep well of scientific expertise.

Rule-out Relief: Novel Personalized Alzheimer’s Testing
Biomarkers have long held the promise of deciphering Alzheimer’s disease (AD). Labcorp, in partnership with Cx Precision Medicine, is beginning to fulfill that promise. The test evaluates blood-based biomarkers using a proprietary algorithm to rule patients out of having AD.

 Session Abstract – PMWC 2022 Silicon Valley

The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative